Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors
by Christina Black | Nov 10, 2021
Novel immunotherapeutic targets in cancer of unknown primary (CUP)
by Christina Black | Nov 10, 2021
Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implication
by Christina Black | Sep 17, 2021
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
by Christina Black | May 27, 2021
Follow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz